<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571389</url>
  </required_header>
  <id_info>
    <org_study_id>BioCytics 0001</org_study_id>
    <secondary_id>WIRB Protocol # 20070969</secondary_id>
    <nct_id>NCT00571389</nct_id>
  </id_info>
  <brief_title>Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products</brief_title>
  <official_title>A Study to Facilitate Development of an Ex-Vivo Device Platform for Circulating Tumor Cell and Immune Cell Harvesting, Banking, and Apoptosis-Viability Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCytics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCytics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      This is a study to investigate the feasibility of harvesting, expanding in culture, and&#xD;
      freezing circulating tumor cells and immune cells from cancer patients and healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Healthy Donors</condition>
  <condition>COVID-19 Donors</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral whole blood, immune cells, circulating tumor cells, discarded tissue obtained from&#xD;
      biopsies and fluid (paracentesis, pleuracentesis), plasma-leukapheresis products, saliva,&#xD;
      urine and stool.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population of patients to be enrolled for this study will be adults (males and females)&#xD;
        with histological proven solid tumors of any stage, seen for routine cancer care at&#xD;
        participating community cancer clinic sites. Patients on clinical trials with experimental&#xD;
        study drugs will be allowed to participate in this observational prospective study.&#xD;
&#xD;
        Healthy volunteers will also make up a portion of the study population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Biospecimen(s) collection:&#xD;
&#xD;
          -  Histological diagnosis of metastatic stage IV or locally advanced (unresectable) stage&#xD;
             III cancer of any solid tumor type, histological non-metastatic cancer of any solid&#xD;
             tumor type of any stage and healthy volunteers&#xD;
&#xD;
          -  Age ≥ 18yo&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ECOG Performance Status of 0, 1, 2, or 3 (Appendix 2)&#xD;
&#xD;
          -  Negative serology screening test for HIV, HBV and HCV; in event of a postive result, a&#xD;
             reflex PCR may be performed and if negative, the pt may be allowed on the study&#xD;
&#xD;
        Additional Subject Eligibility for Leukapheresis Collection:&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Screening laboratory values must meet following criteria on leukapheresis collection&#xD;
             day:&#xD;
&#xD;
               -  WBC ≥ 2000/µL&#xD;
&#xD;
               -  Neutrophils ≥ 1500/µL&#xD;
&#xD;
               -  Platelets ≥ 100 x103/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Creatinine ≤ 2.5 x ULN&#xD;
&#xD;
               -  AST ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases&#xD;
&#xD;
               -  Bilirubin ≤ 2 x ULN (except patients with Gilbert's syndrome, who must have total&#xD;
                  bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any active infection requiring therapy (fever, localizing source) will&#xD;
             be excluded until the infection resolves.&#xD;
&#xD;
          -  Confirmed PCR test result for HIV, HBV or HCV&#xD;
&#xD;
          -  Underlying medical condition that, in the Principal Investigator's or treating&#xD;
             oncologist's opinion, will obscure the interpretation of the patient's safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Powderly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolina BioOncology Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Powderly, MD</last_name>
    <phone>704-947-6599</phone>
    <email>jpowderly@carolinabiooncology.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle Emery, MD, CCRC</last_name>
      <phone>704-947-6599</phone>
      <phone_ext>1147</phone_ext>
      <email>remery@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>Rochelle Emery, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.carolinabiooncology.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>All Stages of cancer</keyword>
  <keyword>All stages of solid tumor origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

